☰

Craig W. Day, Ph.D. - Publications

Affiliations: 
2006 Utah State University, Logan, UT, United States 
Area:
Microbiology Biology, Genetics
Tree Info Similar researchers PubMed Report error

34 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Moquin SA, Simon O, Karuna R, Lakshminarayana SB, Yokokawa F, Wang F, Saravanan C, Zhang J, Day CW, Chan K, Wang QY, Lu S, Dong H, Wan KF, Lim SP, et al. NITD-688, a pan-serotype inhibitor of the dengue virus NS4B protein, shows favorable pharmacokinetics and efficacy in preclinical animal models. Science Translational Medicine. 13. PMID 33536278 DOI: 10.1126/scitranslmed.abb2181  0.39
2018 Evans WJ, Hurst BL, Peterson CJ, Van Wettere AJ, Day CW, Smee DF, Tarbet EB. Development of a respiratory disease model for enterovirus D68 in 4-week-Old mice for evaluation of antiviral therapies. Antiviral Research. PMID 30521834 DOI: 10.1016/J.Antiviral.2018.11.012  0.524
2017 Cryer M, Lane K, Greer M, Cates R, Burt S, Andrus M, Zou J, Rogers P, Hansen MD, Burgado J, Panayampalli SS, Day CW, Smee DF, Johnson BF. Isolation and identification of compounds from Kalanchoe pinnata having human alphaherpesvirus and vaccinia virus antiviral activity. Pharmaceutical Biology. 55: 1586-1591. PMID 28395583 DOI: 10.1080/13880209.2017.1310907  0.413
2017 Smee DF, Hurst BL, Evans WJ, Clyde N, Wright S, Peterson C, Jung KH, Day CW. Evaluation of Cell Viability Dyes in Antiviral Assays with RNA Viruses that Exhibit Different Cytopathogenic Properties. Journal of Virological Methods. PMID 28359770 DOI: 10.1016/J.Jviromet.2017.03.012  0.501
2016 Warfield KL, Barnard DL, Enterlein SG, Smee DF, Khaliq M, Sampath A, Callahan MV, Ramstedt U, Day CW. The Iminosugar UV-4 is a Broad Inhibitor of Influenza A and B Viruses ex Vivo and in Mice. Viruses. 8. PMID 27072420 DOI: 10.3390/V8030071  0.46
2016 Smee DF, Evans WJ, Nicolaou KC, Tarbet EB, Day CW. Susceptibilities of enterovirus D68, enterovirus 71, and rhinovirus 87 strains to various antiviral compounds. Antiviral Research. PMID 27063860 DOI: 10.1016/J.Antiviral.2016.04.003  0.401
2014 Smee DF, Hurst BL, Day CW, Geiben-Lynn R. Influenza Virus H1N1 inhibition by serine protease inhibitor (serpin) antithrombin III. International Trends in Immunity. 2: 83-86. PMID 24883334  0.431
2014 Krajczyk A, Kulinska K, Kulinski T, Hurst BL, Day CW, Smee DF, Ostrowski T, Januszczyk P, Zeidler J. Antivirally active ribavirin analogues--4,5-disubstituted 1,2,3-triazole nucleosides: biological evaluation against certain respiratory viruses and computational modelling. Antiviral Chemistry & Chemotherapy. 23: 161-71. PMID 23538746 DOI: 10.3851/Imp2564  0.404
2013 Havrylyuk D, Zimenkovsky B, Vasylenko O, Day CW, Smee DF, Grellier P, Lesyk R. Synthesis and biological activity evaluation of 5-pyrazoline substituted 4-thiazolidinones. European Journal of Medicinal Chemistry. 66: 228-37. PMID 23811085 DOI: 10.1016/J.Ejmech.2013.05.044  0.36
2013 Kesel AJ, Weiss HC, Schönleber A, Day CW, Barnard DL, Detorio MA, Schinazi RF. Antiviral agents derived from novel 1-adamantyl singlet nitrenes. Antiviral Chemistry & Chemotherapy. 23: 113-28. PMID 23234699 DOI: 10.3851/Imp2485  0.497
2012 Smee DF, Hurst BL, Day CW. D282, a non-nucleoside inhibitor of influenza virus infection that interferes with de novo pyrimidine biosynthesis. Antiviral Chemistry & Chemotherapy. 22: 263-72. PMID 22516927 DOI: 10.3851/Imp2105  0.503
2011 Kumaki Y, Day CW, Smee DF, Morrey JD, Barnard DL. In vitro and in vivo efficacy of fluorodeoxycytidine analogs against highly pathogenic avian influenza H5N1, seasonal, and pandemic H1N1 virus infections. Antiviral Research. 92: 329-40. PMID 21925541 DOI: 10.1016/J.Antiviral.2011.09.001  0.707
2010 London NR, Zhu W, Bozza FA, Smith MC, Greif DM, Sorensen LK, Chen L, Kaminoh Y, Chan AC, Passi SF, Day CW, Barnard DL, Zimmerman GA, Krasnow MA, Li DY. Targeting Robo4-dependent Slit signaling to survive the cytokine storm in sepsis and influenza. Science Translational Medicine. 2: 23ra19. PMID 20375003 DOI: 10.1126/Scitranslmed.3000678  0.317
2010 Kumaki Y, Day CW, Bailey KW, Wandersee MK, Wong MH, Madsen JR, Madsen JS, Nelson NM, Hoopes JD, Woolcott JD, McLean TZ, Blatt LM, Salazar AM, Smee DF, Barnard DL. Induction of interferon-gamma-inducible protein 10 by SARS-CoV infection, interferon alfacon 1 and interferon inducer in human bronchial epithelial Calu-3 cells and BALB/c mice. Antiviral Chemistry & Chemotherapy. 20: 169-77. PMID 20231782 DOI: 10.3851/Imp1477  0.462
2010 Rao JR, Jha AK, Rawal RK, Sharon A, Day CW, Barnard DL, Smee DF, Chu CK. (-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu). Bioorganic & Medicinal Chemistry Letters. 20: 2601-4. PMID 20231094 DOI: 10.1016/J.Bmcl.2010.02.074  0.469
2009 Day CW, Baric R, Cai SX, Frieman M, Kumaki Y, Morrey JD, Smee DF, Barnard DL. A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo. Virology. 395: 210-22. PMID 19853271 DOI: 10.1016/J.Virol.2009.09.023  0.599
2009 Rao J, Jha A, Sharon A, Day C, Bernard D, Smee D, Chu C. Anti-H5N1 Influenza Virus Activity of Carbocyclic Cytosine Nucleosides Antiviral Research. 82: A62-A63. DOI: 10.1016/J.Antiviral.2009.02.150  0.474
2009 Kumaki Y, Day CW, Wandersee MK, Madsen JR, Woolcott JD, Hoopes JD, Bailey KW, Wong M, Smee DF, Morrey JD, Barnard DL. Induction of Interferon Gamma Inducible Protein 10 by SARS-CoV Infection, Interferon Alfacon 1 and Interferon Inducer in Human Bronchial Epithelial Calu-3 Cells and BALB/c Mice Antiviral Research. 82: A34. DOI: 10.1016/J.Antiviral.2009.02.064  0.613
2008 Julander JG, Bowen RA, Rao JR, Day C, Shafer K, Smee DF, Morrey JD, Chu CK. Treatment of Venezuelan equine encephalitis virus infection with (-)-carbodine. Antiviral Research. 80: 309-15. PMID 18675850 DOI: 10.1016/J.Antiviral.2008.07.002  0.755
2008 Barnard DL, Day CW, Bailey K, Heiner M, Montgomery R, Lauridsen L, Jung KH, Li JK, Chan PK, Sidwell RW. Is the anti-psychotic, 10-(3-(dimethylamino)propyl)phenothiazine (promazine), a potential drug with which to treat SARS infections? Lack of efficacy of promazine on SARS-CoV replication in a mouse model. Antiviral Research. 79: 105-13. PMID 18423639 DOI: 10.1016/J.Antiviral.2007.12.005  0.51
2008 Kumaki Y, Day CW, Wandersee MK, Schow BP, Madsen JS, Grant D, Roth JP, Smee DF, Blatt LM, Barnard DL. Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells. Biochemical and Biophysical Research Communications. 371: 110-3. PMID 18406349 DOI: 10.1016/J.Bbrc.2008.04.006  0.457
2008 Chu C, Rao J, Day C, Barnard D, Smee D. Antiviral Activity of (−)-d-Carbocyclic Cytosine (Carbodine) Against Avian Influenza Virus (H5N1) Antiviral Research. 78: A55. DOI: 10.1016/J.ANTIVIRAL.2008.01.114  0.372
2008 Barnard D, Day C, Wandersee M, Kumaki Y, Salazar A. Evaluation of Interferon Inducers, Ribavirin and Mouse Hyperimmune Serum in a Pathogenesis/Lethal Mouse Model Using a Mouse-adapted SARS-CoV Antiviral Research. 78: A20. DOI: 10.1016/J.Antiviral.2008.01.025  0.358
2007 Selvam P, Vijayalakshimi P, Smee DF, Gowen BB, Julander JG, Day CW, Barnard DL. Novel 3-sulphonamido-quinazolin-4(3H)-one derivatives: microwave-assisted synthesis and evaluation of antiviral activities against respiratory and biodefense viruses. Antiviral Chemistry & Chemotherapy. 18: 301-5. PMID 18046963 DOI: 10.1177/095632020701800506  0.668
2007 Barnard DL, Wong MH, Bailey K, Day CW, Sidwell RW, Hickok SS, Hall TJ. Effect of oral gavage treatment with ZnAL42 and other metallo-ion formulations on influenza A H5N1 and H1N1 virus infections in mice. Antiviral Chemistry & Chemotherapy. 18: 125-32. PMID 17626596 DOI: 10.1177/095632020701800302  0.58
2007 Sidwell RW, Barnard DL, Day CW, Smee DF, Bailey KW, Wong MH, Morrey JD, Furuta Y. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrobial Agents and Chemotherapy. 51: 845-51. PMID 17194832 DOI: 10.1128/Aac.01051-06  0.704
2007 SELVAM P, SMEE D, GOWEN B, DAY C, BARNARD D, MORREY J. Design, Synthesis, Antiviral Activity and Cytotoxicity of Novel Sulphonamide Derivatives Antiviral Research. 74: A81-A81. DOI: 10.1016/J.Antiviral.2007.01.139  0.553
2006 Barnard DL, Day CW, Bailey K, Heiner M, Montgomery R, Lauridsen L, Chan PK, Sidwell RW. Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice. Antiviral Chemistry & Chemotherapy. 17: 275-84. PMID 17176632 DOI: 10.1177/095632020601700505  0.554
2006 Barnard DL, Day CW, Bailey K, Heiner M, Montgomery R, Lauridsen L, Winslow S, Hoopes J, Li JK, Lee J, Carson DA, Cottam HB, Sidwell RW. Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin. Antiviral Research. 71: 53-63. PMID 16621037 DOI: 10.1016/J.Antiviral.2006.03.001  0.534
2005 Day CW, Smee DF, Julander JG, Yamshchikov VF, Sidwell RW, Morrey JD. Error-prone replication of West Nile virus caused by ribavirin. Antiviral Research. 67: 38-45. PMID 15919121 DOI: 10.1016/J.Antiviral.2005.04.002  0.717
2005 Julander JG, Winger QA, Olsen AL, Day CW, Sidwell RW, Morrey JD. Treatment of West Nile virus-infected mice with reactive immunoglobulin reduces fetal titers and increases dam survival. Antiviral Research. 65: 79-85. PMID 15708634 DOI: 10.1016/J.Antiviral.2004.10.005  0.733
2004 Morrey JD, Day CW, Julander JG, Olsen AL, Sidwell RW, Cheney CD, Blatt LM. Modeling hamsters for evaluating West Nile virus therapies. Antiviral Research. 63: 41-50. PMID 15196819 DOI: 10.1016/J.Antiviral.2004.02.005  0.727
2004 Morrey JD, Day CW, Julander JG, Blatt LM, Smee DF, Sidwell RW. Effect of interferon-alpha and interferon-inducers on West Nile virus in mouse and hamster animal models. Antiviral Chemistry & Chemotherapy. 15: 101-9. PMID 15185728 DOI: 10.1177/095632020401500202  0.723
2003 BLATT L, TAN H, HONG J, DERRICK J, SEIWERT S, DAY C, MORREY J, GROSSE W, SANDA C, TAYLOR M. 292 Synergistic effects of type 1 (infergen(R)) and type 2 (actimmune(R)) interferons in preclinical models of HCV: demonstration of potential efficacy Hepatology. 38: 296-297. DOI: 10.1016/S0270-9139(03)80335-X  0.51
Show low-probability matches.